

# Global Influenza Surveillance and Response System (GISRS)

## Situation update on integrated sentinel surveillance of influenza and SARS-CoV-2 in SEAR MS


( Till Monday, January 30, 2023)

Infectious Hazard Management (IHM)


WHO Health Emergency Programme

[SeFlu@who.int](mailto:SeFlu@who.int)


Number and the proportion of Influenza like Illness ( ILI ) cases per 1,000 outpatients, SEAR




## Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, SEAR




## Number of ILI/SARI \* specimens processed for testing by week and year, SEAR



# Number of specimens positive for influenza by subtypes and the Percentage positive, SEAR




# Number and Percentage of ILI/SARI samples positive\* for SARS COV-2 , SEAR




*\*Includes ILI/SARI samples tested for SARS-COV2 by Bangladesh, Bhutan, Indonesia Nepal and Timor-Leste as a part of integrated sentinel surveillance of influenza and COVID-19*


# Number of ILI/SARI specimens processed for testing by week and year, Bangladesh




## Number and the proportion of ILI cases per 1,000 outpatients, Bangladesh




## Number and the proportion of SARI cases per 100 inpatients, Bangladesh



## Number of specimens positive for influenza by subtypes and Percentage positive, Bangladesh




## Number and Percentage of ILI/SARI samples positive for SARS COV-2 , Bangladesh




*\*Includes ILI/SARI samples tested for SARS-COV2  
as a part of integrated sentinel surveillance of influenza and COVID-19*

Source: WHO/GISRS FluMart - last data submission on [30/01/2023](#)


## Number and proportion of ILI cases per 1,000 outpatients, [Bhutan](#)




## Number and proportion of SARI cases per 100 inpatients, Bhutan




## Number of ILI/SARI \* specimens processed for testing by week and year, Bhutan



## Number of specimens positive for influenza by subtypes and the Percentage positive, Bhutan




## Number and Percentage of ILI/SARI samples positive for SARS COV-2\*, Bhutan




*\*Includes ILI/SARI samples tested for SARS-COV2  
as a part of integrated sentinel surveillance of influenza and COVID-19*

Source: WHO/GISRS FluMart - last data submission on [30/01/2023](#)


## Number and proportion of ILI cases per 1,000 outpatients, [DPR Korea](#)




## Number and proportion of SARI cases per 100 inpatients, [DPR Korea](#)




## Number of ILI/SARI \* specimens processed for testing by week and year, DPR Korea




## Number of specimens positive for influenza by subtypes and the Percentage positive, DPR Korea




# Number of ILI/SARI \* specimens processed for testing by week and year, India




## Number of specimens positive for influenza by subtypes and the Percentage positive, India




Number and proportion of ILI cases per 1,000 outpatients, Indonesia




## Number and proportion of SARI cases per 100 inpatients, Indonesia




## Number of ILI/SARI \* specimens processed for testing by week and year, Indonesia




## Number of specimens positive for influenza by subtypes and the Percentage positive, Indonesia




# Number of ILI/SARI \* specimens processed for testing by week and year, Maldives




## Number of specimens positive for influenza by subtypes and the Percentage positive, Maldives




# Number of ILI/SARI \* specimens processed for testing by week and year, Myanmar




## Number of specimens positive for influenza by subtypes and the Percentage positive, Myanmar




Number and proportion of ILI cases per 1,000 outpatients, [Nepal](#)




Number and proportion of SARI cases per 100 inpatients, [Nepal](#)




# Number of ILI/SARI \* specimens processed for testing by week and year, Nepal



## Number of specimens positive for influenza by subtypes and the Percentage positive, Nepal




## Number and Percentage of ILI/SARI samples positive for SARS COV-2, Nepal




*\*Includes ILI/SARI samples tested for SARS-COV2  
as a part of integrated sentinel surveillance of influenza and COVID-19*

Source: WHO/GISRS FluMart - last data submission on [30/01/2023](#)


## Number and proportion of ILI cases per 1,000 outpatients, Sri Lanka




## Number and proportion of SARI cases per 100 inpatients, Sri Lanka




# Number of ILI/SARI \* specimens processed for testing by week and year, Sri Lanka




## Number of specimens positive for influenza by subtypes and the Percentage positive, Sri Lanka




## Number of ILI/SARI \* specimens processed for testing by week and year, Thailand




## Number of specimens positive for influenza by subtypes and the Percentage positive, Thailand




## Number and proportion of ILI cases per 1,000 outpatients, Timor-Leste




## Number and proportion of SARI cases per 100 inpatients, [Timor-Leste](#)




# Number of ILI/SARI \* specimens processed for testing by week and year, Timor-Leste



## Number of specimens positive for influenza by subtypes and the Percentage positive, , Timor-Leste



# Number and Percentage of ILI/SARI samples positive for SARS COV-2\* , Timor-Leste



\*Includes ILI/SARI samples tested for SARS-COV2  
as a part of integrated sentinel surveillance of influenza and COVID-19

Source: WHO/GISRS FluMart - last data submission on [30/01/2023](#)

If you have any comment or suggestion  
Please write to [SeFlu@who.int](mailto:SeFlu@who.int)